LY3473329

DRUG5 trials

Sponsors

Eli Lilly and Company

Conditions

HealthyLipoprotein DisorderRenal Insufficiency

Phase 1

A Study of LY3473329 in Healthy Participants

CompletedNCT04472676

Eli Lilly and CompanyHealthy

Start: 2020-08-18End: 2021-11-09Updated: 2021-12-14

A Study of LY3473329 in Healthy Japanese Participants

CompletedNCT05038787

Eli Lilly and CompanyHealthy

Start: 2021-11-11End: 2022-04-07Updated: 2022-06-21

A Study of LY3473329 in Participants With Impaired and Normal Renal Function

CompletedNCT05778864

Eli Lilly and CompanyRenal Insufficiency

Start: 2023-03-17End: 2024-09-06Updated: 2024-10-28

A Study of Carbon-14-Labelled [14C] LY3473329 in Healthy Male Participants

CompletedNCT06342596

Eli Lilly and CompanyHealthy

Start: 2024-03-05End: 2024-05-01Updated: 2024-05-30

Phase 2

A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

CompletedNCT05563246

Eli Lilly and CompanyLipoprotein Disorder

Start: 2022-11-24End: 2024-03-14Updated: 2025-03-25

Related Papers

Oral Muvalaplin for Lowering of Lipoprotein(a)

JAMA2024-11-1880 citations

Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation

JAMA2023-08-28158 citations